Feb. 26, 2021–Hologic has completed its acquisition of Biotheranostics for about $230 million. Biotheranostics develops and markets Breast Cancer Index and CancerType ID, two molecular diagnostic tests for breast and metastatic cancers.
Breast Cancer Index is recommended by the NCCN for prediction of which early-stage hormone receptor positive breast cancer patients are likely to benefit from extended endocrine therapy. The test is also included in guidelines from the American Society for Clinical Oncology.
The CancerType ID test provides a molecular diagnosis for patients with uncertain or unknown cancers. The test compares genomic tumor information with a reference database to find the closest match.
“We are very pleased to complete the acquisition of Biotheranostics and look forward to working with our new colleagues to grow in the large, rapidly expanding oncology space,” Kevin Thornal, president of Hologic’s diagnostic solutions division, said in a press statement. “We are even more excited about the acquisition because last month the National Comprehensive Cancer Network revised its clinical practice guidelines to include Breast Cancer Index as the only gene expression assay to predict benefit from extended endocrine therapy for patients with early-stage hormone-receptor positive breast cancer.”
Both tests are laboratory-developed tests that are not required to be cleared or approved by the FDA.